Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.07. | Procaps Group, S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
28.06. | Procaps Group Appoints Jose Minski To Succeed Ruben Minski As Executive Chairman | - | RTTNews | ||
28.06. | Procaps says exec chair Ruben Minski resigns | 1 | Seeking Alpha | ||
28.06. | Procaps Group, S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
14.05. | Procaps Group, S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
01.05. | Procaps Group, S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
04.03. | Procaps Group, S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
05.02. | Procaps Group appoints Jose Vieira as CEO | 2 | Investing.com | ||
26.12.23 | Procaps Group Reports Third Quarter 2023 Results | 257 | Business Wire | MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group, S.A. (NASDAQ: PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company... ► Artikel lesen | |
16.10.23 | Procaps Group to Participate at CPHI Barcelona 2023 | 327 | Business Wire | Procaps Group (NASDAQ: PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today that it will participate at the CPHI Barcelona 2023, that will take... ► Artikel lesen | |
05.09.23 | Procaps Group Reports Second Quarter 2023 Results | 258 | Business Wire | MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group, S.A. (NASDAQ: PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
AURORA CANNABIS | 5,410 | -0,55 % | Vor den Zahlen: Bahnt sich bei Canopy Growth, Aurora Cannabis & Co. die Trendwende an? | © Foto: adobe.stock.comDie US-Wahlen werfen ihre Schatten voraus. Auch im Cannabis-Sektor verfolgt man die aktuellen Entwicklungen mit Argusaugen. Zuletzt ließ eine Meldung die Kurse von Canopy Growth... ► Artikel lesen | |
CANOPY GROWTH | 6,750 | +0,45 % | Stocks in Play: Canopy Growth Corporation | ||
TILRAY BRANDS | 1,681 | -0,53 % | Tilray Brands, Inc.: Tilray erhält erste neue Cannabis-Anbaulizenz in Deutschland nach neuen Vorschriften | Aphria RX-Anlage von Tilray in Deutschland erhält neue Cannabis-Anbaulizenz, die eine ca. 5-fache Produktionssteigerung und neue Sorten ermöglicht, um den Zugang für Patienten im ganzen Land zu verbessern
Aphria... ► Artikel lesen | |
TEVA | 15,750 | -0,32 % | Teva Pharmaceutical Industries Limited: Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease | Enrollment acceleration drives earlier-than-anticipated data availability for this potentially best-in-class IBD treatment
Topline results for both UC and CD now anticipated in Q4 2024... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 458,75 | +0,54 % | Is Vertex Pharmaceuticals' Monopoly in Danger? | ||
CRONOS GROUP | 2,202 | -1,43 % | Cronos Group Inc: Cronos to hold Q2 results call Aug. 8 | ||
VIATRIS | 11,150 | +0,18 % | Kursgewinne für die Viatris-Aktie (11,0505 €) | Am US-amerikanischen Aktienmarkt notiert die Aktie von Viatris derzeit ein wenig fester. Der jüngste Kurs betrug 12,00 US-Dollar. Ein Kursplus in Höhe von 24 Cent erfreut derzeit die Aktionäre von Viatris.... ► Artikel lesen | |
INCYTE | 63,54 | +0,54 % | Analyst Ratings For Incyte | ||
BAUSCH HEALTH | 5,533 | +0,20 % | Bausch Health Companies Inc.: Bausch Health Responds to Market Rumors | LAVAL, QC / ACCESSWIRE / July 24, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") has become aware of a news article issued by Reorg® today, citing unnamed sources.The article... ► Artikel lesen | |
XTACY THERAPEUTICS | 0,017 | 0,00 % | Xtacy Therapeutics Corp: Xtacy adjusts shares-for-debt deal to be for $179,025 | ||
CRESCO LABS | 1,455 | -1,36 % | Cresco Labs Inc: Cresco Labs to release Q2 2024 financial results Aug. 8 | ||
IONIS PHARMACEUTICALS | 47,230 | -0,32 % | Ionis Pharmaceuticals, Inc.: Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome | ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set of assessment tools that collect input from... ► Artikel lesen | |
ALNYLAM PHARMACEUTICALS | 219,00 | +1,25 % | Aktienreport-Tipp Alnylam nicht zu bremsen - Bayer überholt | Seit der Vorlage positiver Phase-3-Studiendaten ist die Aktie des amerikanischen Biotech-Unternehmens Alnylam nicht zu bremsen (DER AKTIONÄR berichtete). Am Dienstag stieg die Marktkapitalisierung des... ► Artikel lesen | |
NEKTAR THERAPEUTICS | 1,276 | +0,79 % | Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 | - NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism -
- IND-Enabling Studies Underway for NKTR-0165 with First-in-Human Studies Planned in First Half... ► Artikel lesen | |
ORAMED PHARMACEUTICALS | 2,326 | -0,13 % | Oramed Pharmaceuticals Inc.: Oramed Letter to Shareholders | Stock Repurchase Program
Scilex Senior Secured Note
Phase 3 Oral Insulin Trial in US
JV with Chinese Partner, HTIT
NEW YORK, June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq:... ► Artikel lesen |